b'Scientific Session Abstracts SATURDAY APRIL 20, 2024 degeneration. Therefore, delaying TEVAR may reduce periprocedural risks, except for patients with early aneurysmal degeneration. Further studies are needed to validate these findings and help guide clinical decision-making for the timing of TEVAR for uTBAD.Table 1. Baseline characteristics per TEVAR timingTEVAR timing 14 days 14 - 30 days 30 daysN=1,304 N=188 N=362 p-valueDemographic VariablesAge (years) 62.113.7 60.513.2 60.212.1 0.027Gender (male) 806 (61.8%) 126 (67.0%) 212 (58.6%) 0.152BMI (kg/m2) 29.67.1 29.57.1 29.86.7 0.914Ethnicity (Hispanic or Latino) 94 (7.2%) 9 (4.8%) 27 (7.5%) 0.446White 691 (52.9%) 109 (57.9%) 201 (55.5%)Race Black 457 (35.1%) 57 (30.3%) 116 (32.0%) 0.627Other 156 (11.9%) 22 (11.7%) 45 (12.4%)Medical HistorySmoking 799 (61.3%) 109 (57.9%) 240 (66.3%) 0.110COPD 213 (16.3%) 30 (15.9%) 62 (17.1%) 0.920DM 164 (12.6%) 25 (13.3%) 64 (17.7%) 0.043HTN 1,158 (88.8%) 173 (92.0%) 350 (96.7%) 0.001HD 50 (3.8%) 6 (3.2%) 14 (3.9%) 0.906Preoperative hemoglobin (g/dl) 11.51.9 10.91.9 11.61.9 0.001Preoperative creatinine 1.20.8 1.20.7 1.10.6 0.069(mg/dl)None 1,148168 (89.4%) 323 (89.2%)(88.0%)CAD History of MI 119 (9.1%) 10 (5.3%) 28 (7.7%) 0.040Stable angina 23 (1.8%) 3 (1.6%) 8 (2.2%)Unstable angina 14 (1.1%) 7 (3.7%) 3 (0.8%)None 1,187 (91.0%) 169 (89.9%) 321 (88.7%)Asymptomatic 78 (5.9%) 12 (6.4%) 20 (5.5%)CHF Mild 20 (1.5%) 4 (2.1%) 15 (4.1%) 0.142Moderate or19 (1.5%) 3 (1.6%) 6 (1.7%)severeNone 1,189 (91.2%) 173 (92.0%) 334 (92.3%)Stroke without71 (5.4%) 10 (5.3%) 15 (4.1%)CVD deficit 0.860Stroke with44 (3.4%) 5 (2.7%) 13 (3.6%)deficit52SOUTHERN CALIFORNIA VASCULAR SURGICAL SOCIETY'